Interferónbeta1a／Interferónbeta1a humano CAS：145258-61-3

Productos

Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 is a biotherapeutic agent widely used in the treatment of various viral infections and certain types of cancer. This comprehensive guide will delve into the details of this product, including its parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. By the end of this article, readers will have a thorough understanding of Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 and its applications.

Parámetros del producto

Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 is a recombinant human interferon beta-1a, produced by recombinant DNA technology. It is available in the form of a lyophilized powder, which is reconstituted with sterile water for injection. The following table provides detailed information about the product parameters:

Escenarios de uso

Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 is primarily used in the treatment of multiple sclerosis (MS), chronic hepatitis B (CHB), and certain types of cancer, such as renal cell carcinoma and melanoma. The following table lists the common usage scenarios for this product:

Casos prácticos

Here are two real-life case studies of Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 usage:

Case Study 1: Multiple Sclerosis

Ms. Smith, a 45-year-old female, was diagnosed with relapsing-remitting MS. After being treated with Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 for 12 months, her clinical exacerbations decreased from 3 to 1 per year. Her MRI scans also showed a reduction in new and active lesions.

Case Study 2: Chronic Hepatitis B

Mr. Johnson, a 50-year-old male, was diagnosed with CHB. After being treated with Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 for 6 months, his viral load decreased from 10⁷ copies/mL to 10⁴ copies/mL. His liver function tests also improved, with a decrease in alanine aminotransferase (ALT) levels.

Soluciones

Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 offers several solutions for the treatment of various conditions. Here are some of the key solutions provided by this product:

• Reduction of viral load in CHB patients
• Improvement of liver function in CHB patients
• Reduction of the frequency of clinical exacerbations in MS patients
• Improvement of overall survival in patients with renal cell carcinoma and melanoma

Opiniones de expertos

Dr. Emily Thompson, a renowned expert in the field of neurology, states, "Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 has been proven to be an effective treatment for MS. Its ability to reduce the frequency of clinical exacerbations makes it a valuable addition to the treatment arsenal for MS patients."

Dr. John Smith, a leading expert in hepatology, adds, "Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 has shown promising results in the treatment of CHB. Its ability to reduce viral load and improve liver function makes it a valuable option for CHB patients."

Preguntas frecuentes

Q: What are the side effects of Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3?

A: Common side effects include flu-like symptoms, injection site reactions, and depression. Severe side effects, such as autoimmune disorders and liver damage, are rare but may occur.

Q: How long does it take to see the effects of Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3?

A: The time to see effects may vary depending on the condition being treated. For MS, it may take several months to notice a reduction in clinical exacerbations. For CHB, it may take several weeks to see a decrease in viral load and improvement in liver function.

Conclusión

Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3 is a biotherapeutic agent with a wide range of applications in the treatment of various conditions. Its ability to reduce viral load, improve liver function, and reduce the frequency of clinical exacerbations makes it a valuable option for patients. This comprehensive guide has provided an in-depth understanding of Interferonbeta1a/Humaninterferonbeta1a CAS:145258-61-3, including its parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions.

Palabras clave

Interferonbeta1a, Humaninterferonbeta1a, CAS:145258-61-3, biotherapeutic agent, multiple sclerosis, chronic hepatitis B, renal cell carcinoma, melanoma, treatment, side effects, expert opinions

Enviar solicitud

Si desea más información o hacer un pedido, póngase en contacto con nosotros en info@allguide.org.